We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Cisco Systems, Abbott Laboratories and Coca-Cola
Read MoreHide Full Article
For Immediate Release
Chicago, IL – January 27, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Cisco Systems, Inc. (CSCO - Free Report) , Abbott Laboratories (ABT - Free Report) and The Coca-Cola Co. (KO - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Cisco, Abbott and Coca-Cola
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems, Inc., Abbott Laboratories and The Coca-Cola Co.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Cisco's shares have outperformed the Zacks Computer - Networking industry over the past year (+31.2% vs. +23.9%). The company's business model has evolved with subscriptions accounting for more than half of its total revenues. Increases in its recurring revenue base bodes well for investors. Its Splunk acquisition enhances its recurring revenue base.
The buyout significantly expands Cisco's portfolio of software-based solutions, contributing more than $4 billion in ARR and making it one of the largest software companies in the world. The launch of AI-powered Hypershield, which combines security and networking, strengthened Cisco's security portfolio.
However, it has been suffering from sluggish networking sales, primarily due to lackluster demand from telecommunication and cable services providers, as well as stiff competition. Cisco's prospects are further challenged in the AI-driven networking space due to stiffening competition.
Shares of Abbott have outperformed the Zacks Medical - Products industry over the past year (+21.3% vs. +18.6%). The company's pipeline is unlocking new growth opportunities, supporting the company's positive momentum and strong growth outlook for 2025. Freestyle Libre, Lingo and Libre Rio CGM devices are on a great trajectory. Alinity, the company's next-generation suite of systems, is a key driver in the core lab diagnostics business.
The company is optimistic about its latest progress with biosimilars and expects this to significantly boost EPD sales, beginning 2025. Within Nutrition, despite softness in its international pediatric segment, Abbott is regaining market share banking on a strong Adult Nutrition business.
Yet the significant runoff of COVID-19 testing-related sales is hurting Abbott's Diagnostics growth. Headwinds such as tough macro conditions and foreign exchange also add to the worry.
Coca-Cola's shares have outperformed the Zacks Beverages - Soft drinks industry over the past year (+6.3% vs. -4.6%). The company experiences positive business trends, as evident by its strong track record of beating expectations. In third-quarter 2024, the company exceeded sales and earnings estimates for the seventh consecutive quarter, with earnings showing year-over-year improvement.
Results benefited from continued business momentum, aided by higher pricing across markets facing intense inflation and favorable mix. KO is well-poised to benefit from its marketing and innovation strategies, and growing digital investments. It has provided an optimistic view for 2024.
It expects organic revenue growth of 10% for 2024, with comparable EPS to grow 5-6%. However, Coca-Cola faces inflationary cost pressures due to higher commodity and material costs, as well as increased marketing investments.
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Cisco Systems, Abbott Laboratories and Coca-Cola
For Immediate Release
Chicago, IL – January 27, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Cisco Systems, Inc. (CSCO - Free Report) , Abbott Laboratories (ABT - Free Report) and The Coca-Cola Co. (KO - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Cisco, Abbott and Coca-Cola
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems, Inc., Abbott Laboratories and The Coca-Cola Co.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Today's Featured Research Reports
Cisco's shares have outperformed the Zacks Computer - Networking industry over the past year (+31.2% vs. +23.9%). The company's business model has evolved with subscriptions accounting for more than half of its total revenues. Increases in its recurring revenue base bodes well for investors. Its Splunk acquisition enhances its recurring revenue base.
The buyout significantly expands Cisco's portfolio of software-based solutions, contributing more than $4 billion in ARR and making it one of the largest software companies in the world. The launch of AI-powered Hypershield, which combines security and networking, strengthened Cisco's security portfolio.
However, it has been suffering from sluggish networking sales, primarily due to lackluster demand from telecommunication and cable services providers, as well as stiff competition. Cisco's prospects are further challenged in the AI-driven networking space due to stiffening competition.
(You can read the full research report on Cisco here >>>)
Shares of Abbott have outperformed the Zacks Medical - Products industry over the past year (+21.3% vs. +18.6%). The company's pipeline is unlocking new growth opportunities, supporting the company's positive momentum and strong growth outlook for 2025. Freestyle Libre, Lingo and Libre Rio CGM devices are on a great trajectory. Alinity, the company's next-generation suite of systems, is a key driver in the core lab diagnostics business.
The company is optimistic about its latest progress with biosimilars and expects this to significantly boost EPD sales, beginning 2025. Within Nutrition, despite softness in its international pediatric segment, Abbott is regaining market share banking on a strong Adult Nutrition business.
Yet the significant runoff of COVID-19 testing-related sales is hurting Abbott's Diagnostics growth. Headwinds such as tough macro conditions and foreign exchange also add to the worry.
(You can read the full research report on Abbott here >>>)
Coca-Cola's shares have outperformed the Zacks Beverages - Soft drinks industry over the past year (+6.3% vs. -4.6%). The company experiences positive business trends, as evident by its strong track record of beating expectations. In third-quarter 2024, the company exceeded sales and earnings estimates for the seventh consecutive quarter, with earnings showing year-over-year improvement.
Results benefited from continued business momentum, aided by higher pricing across markets facing intense inflation and favorable mix. KO is well-poised to benefit from its marketing and innovation strategies, and growing digital investments. It has provided an optimistic view for 2024.
It expects organic revenue growth of 10% for 2024, with comparable EPS to grow 5-6%. However, Coca-Cola faces inflationary cost pressures due to higher commodity and material costs, as well as increased marketing investments.
(You can read the full research report on Coca-Cola here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.